Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice
In conclusion, KY-226 exerted anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively.
Source: Journal of Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
More News: Actos | Diabetes | Diets | Eating Disorders & Weight Management | Endocrinology | Hepatocellular Carcinoma | High Fat | Insulin | Liver | Liver Cancer | Nutrition | Obesity | Urology & Nephrology